Eli Lilly other research news

Eli Lilly researchers published in Science their research explaining the ability of the investigational compound raloxifene to act as both an estrogen agonist and antagonist.

In reproductive tissue, raloxifene and certain other compounds act through the estrogen receptor (ER). ER-mediated gene transcription is initiated by the binding of the DNA binding domain of the receptor to a DNA sequence, the estrogen response element (ERE). In reproductive tissue, raloxifene acts as an estrogen antagonist. ...